Lombard Medical Technologies Share Discussion Threads

[skinny] 07/5/2013 14:03

Canaccord Genuity Buy 202.00 203.50 321.00 321.00 Reiterates

[glasswala] 07/5/2013 10:54

The company does not seem to be worried or that what it seems as they are steaming ahead with the launch in the latter part of this year!! or is this typical smokes and screens for an Aim company and we should be very worried!!!!!!!!

Not a single buy and sell-this is spooky!!

[nod] 07/5/2013 10:44

This patent was filed by Medtronic in 1995(Gulp)http://www.google.com/patents/US6306141

[nod] 07/5/2013 10:39

The USPTO gets to decide on the patent after considering objections. Hopefully there will be some objections from within the USA. LMT needs to do lots of lobbying. It is very easy to miss seeing relevant applications. The big companies will try applications in the hope that nobody picks it up and it sails through without a challenge.

[rayrac] 07/5/2013 07:39

What a dirty business the med world is!

Seems to me, we have another US co trying it on via the back door.

[skinny] 07/5/2013 07:05

London, UK, 7 May 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focused on innovative vascular products, today announces that it has filed a petition with the US Patent and Trademark Office (USPTO) for Inter Partes Review of the validity of the broadest claims of US patent No. 6,306,141 ('141 patent), entitled "Medical devices incorporating stress-induced martensite (SIM) alloy elements", which is assigned to Medtronic Inc.

The Company believes that claims of the '141 patent directed to the use of a shape memory alloy exhibiting SIM in a medical device, are invalid because the use of self-expanding shape memory alloys utilizing stress induced martensite (an inherent property of all Nitinol based devices that exhibit thermally induced martensite (TIM)) for medical devices was well known before the patent was filed. As such the claims in the '141 patent are invalid and not entitled to protection under the US patent laws. A final determination by The Patent and Trademark Appeals Board (PTAB) of the validity of the '141 patent will be issued within 18 months after institution of the Review. No counterpart patents to the '141 patent are in force in other territories outside of the US.

Lombard Medical does not believe it infringes the '141 patent and will launch Aorfix™, its lead product for the treatment of abdominal aortic aneurysms (AAAs), in H2 2013 as planned.

[nod] 05/5/2013 07:09

The share price has held above the psychologically important 200p level for one month now. This is good from a TA perspective as it builds a support level - the longer it stays above 200 the stronger the support level becomes in the event of any downward pressure.AGM on 23 May. I don't know where the next news might come from - an offer perhaps.

[nod] 26/4/2013 06:37

What makes you think it's the same person? It could be just a coincidence.:)

[stable] 24/4/2013 12:54

Glaswalla, about to ask the same question, nothing can make sense, unless yesterdays purchases were in error by some funds and they realised and got rid off at the earlist.

[glasswala] 24/4/2013 12:43

What is with this 6109 share purchase and sell in the last two days??? What is going on here!!

[nod] 23/4/2013 00:59

Shorewalk, that value must underpin the share price and make LMT attractive to companies in the same space and looking to expand. There are a few of those. While LMT is small in comparison it would be a tasty little morsel.It's good to see the share price consolidating gains over the past two months.

[shorewalk] 18/4/2013 11:22

Again to remind everyone - this is where much of the companies current and long term value lies. Either not needing to pay tax on profits until well into the future or more likely as value to buyer.
From this years accounts
Taxation losses carried forward at the end of the y
ear amounted to approximately £57m (2011: £49m)
and the unrecognised deferred tax asset at 23% (201
1: 25%) is approximately £13m (2011: £12m).
No deferred tax asset has been recognised in respec
t of these losses as the Directors consider it is,
as yet, uncertain whether the losses will be utilis
ed. Tax losses would be utilised in future periods
against trading profits

[nod] 17/4/2013 06:41

321p. Yes please!

[glasswala] 16/4/2013 14:40

Canaccord Genuity reiterates a buy for LMT but drops price from 333p to 321p. This is definately a good sign!!
I see some one has seen this buy rating from the broker and splashed out for 20000 shares!!! Good luck to that person. I wish i had that kind of dosh sloshing around as i would have some of what he has just got!!

[bmw30csl] 11/4/2013 14:34

its a great story - i just feel it will lack news for a while - good luck to holders - hope to rejoin you later on at a lower entry!

[shorewalk] 11/4/2013 13:05

The comment that they will need funding down the road may and I just say may be an invitation to anyone interested in buying the company at this early stage - eg someone with the sales force already in place, whose own sales might suffer when their stents aren't viewed as favourably. Of course might just be what it says, but I'm old enough to know there is often a second story. Wouldn't want to risk missing an offer so will stay put for now. I respect others have different views.

[bmw30csl] 11/4/2013 12:18

hmm i dont see any need to own this before the new equity is raised. What they have is not sufficient to kick start USA in my opinion.

[glasswala] 11/4/2013 11:13

A slow and steady march upwards would be nice!! How much cash burn a month for this Company and how long will the £14m plus £2.5m raised last for anyone?? Will it be enough for the Push into USA. They have mentioned that a further fund raising is needed to grow the company. I for one would not mind it being done via a rights issue at least that way we shareholders get a slice of the rewards as opposed to the big boys who just come scavenging at parties and take the best morsels!!!

[nod] 10/4/2013 05:18

Nobby - my thoughts too. Europe's been through tough financial times mind. Perhaps users in Europe and Japan will be keener following FDA approval.It was concerning that extra sales didn't flow through to revenue because product taken from stock? I didn't quite get this bit. We're they giving the product away in some cases?

[nobbygnome] 09/4/2013 12:46

It seems to me that the increase in usage in Europe is a little disappointing. You would have thought it would be growing a bit faster than 13% a year. I would be interested in other's thoughts. Obviously the US is the key.....

Nobby

[morigam] 09/4/2013 09:09

Listen to the interview with Lombard Medical Technologies CEO Simon Hubbert on their final results, which have come out today.

[skinny] 09/4/2013 07:01

Operational highlights
· Demand, as measured by patients treated, for Aorfix™ increased 13% in main EU markets (UK, Germany, Italy and Spain) with 382 patients treated (2011: 338 patients)
o Demand was not fully reflected in revenue as it was partly supplied from distributor stock
· Aorfix™ revenue of £2.3m in main EU markets (2011: £2.2m)
o 32% growth in Germany reflecting expansion of direct sales team
· High angle clinical data from US PYTHAGORAS trial presented in June 2012
o Strong data despite extremely challenging patient group with high neck angles
· Launch of Aorflex™ delivery system in April 2012
o Encouraging clinician feedback
· Key hire - appointment of Ian Ardill to the Board asChief Financial Officer in January 2012

Financial highlights
· Total commercial revenue (total revenue less revenue from the clinical trial) flat at £3.9m (2011: £3.9m) despite procedure growth of 13% in main EU markets
· Total revenue declined to £3.9m (2011: £4.0m) due to completion of US trial enrolment and loss of related revenues
· Operating loss decreased by 28% to £8.2m (2011: £11.4m)
· Cash and cash equivalents of £2.7m as at 31 December 2012 (31 December 2011: £7.5m)
· £3.0m raised from issue of convertible loan notes to Invesco Asset Management Limited ("Invesco") in March 2012
· Share consolidation of 1 new ordinary share of 20p for every 200 existing ordinary shares of 0.1p in March 2012
· Six month extension of Long Stop Date of Second Tranche of the May 2011 Fundraising
· Participation of £2.8m by LSP Life Sciences Fund N.V., a specialist healthcare fund, in the Second Tranche of the May 2011 Fundraising

Post period events
· 14 February 2013 - US FDA approval of Aorfix™ for the endovascular repair of AAAs
o Label indication for the treatment of patients with angulations at the neck of the aneurysm from 0 to 90 degrees
o Aorfix™ the only endovascular stent graft licensed in the US for use in cases with neck angulations greater than 60 degrees (consistent with high-angle, 90 degree, label claim in Europe)
· US approval of Aorfix™ has triggered receipt of £14.1m gross funds from the Second Tranche of the May 2011 Fundraising
· Aorfix™ approval in Japan anticipated in 2014
o US approval has triggered receipt of $2.5m from the $5.0m convertible loan facility granted by Medico's Hirata Inc., the Company's distribution partner in Japan

[nod] 08/4/2013 20:13

London, UK, 12 March 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focused on innovative vascular products, will announce its preliminary results for the year ended 31 December 2012 on Tuesday 9 April 2013.